Abstract
B-cell lymphoma-2 (BCL-2) is a critical regulator of apoptosis, and its overexpression is a known driver of cancer cell survival. This study investigates the association between three functional BCL-2 genetic polymorphisms (rs2279115, rs1801018, and rs1564483) and the risk of esophageal squamous cell carcinoma (ESCC). Through a large-scale case-control study in Chinese populations and subsequent functional validation, researchers identified a significant protective effect associated with the rs2279115 AA genotype, which correlates with reduced BCL-2 expression.
Introduction
Esophageal squamous cell carcinoma (ESCC) remains a significant global health challenge, characterized by high aggression and a complex interplay of genetic and environmental risk factors. A fundamental mechanism in oncogenesis is the evasion of programmed cell death, or apoptosis. The BCL-2 gene produces a pro-survival protein that inhibits apoptosis; consequently, genetic variations that lead to its upregulation can facilitate the survival of damaged cells, promoting tumor development.
This research, originally published in Scientific Reports, addresses how common Single Nucleotide Polymorphisms (SNPs) within the regulatory regions of BCL-2 influence ESCC susceptibility. While a recent erratum was issued to correct author institutional affiliations, the core scientific findings regarding the genetic underpinnings of the disease remain robust and insightful.
Methodology
The researchers conducted a candidate-gene association study followed by functional validation in two independent cohorts from China.
Study Population and Genotyping
The study included a total of 3,188 participants, comprising 1,588 ESCC patients and 1,600 cancer-free controls. Three specific polymorphisms—rs2279115, rs1801018, and rs1564483—were genotyped to determine their frequency in both groups.
Statistical and Functional Analysis
Logistic regression was utilized to calculate Odds Ratios (ORs) and 95% Confidence Intervals (CIs), adjusting for confounding factors such as age and sex. To establish a biological link between genotype and phenotype, the team analyzed BCL-2 mRNA expression levels in both normal and cancerous esophageal tissues across different genotypes.
Results and Discussion
Genetic Association with ESCC Risk
The primary finding was a significant association between the rs2279115 polymorphism and ESCC risk. Individuals with the AA genotype exhibited a significantly lower risk compared to those with the CC genotype (OR = 0.72, 95% CI = 0.57–0.90, P = 0.005). This suggests that the "A" allele serves a protective function, providing a roughly 28% reduction in risk compared to the CC genotype.
Gene-Environment Interactions
The protective effect of the rs2279115 AA genotype was notably amplified in specific subgroups:
- Non-smokers: OR = 0.42 (95% CI = 0.29–0.59, P = 0.001)
- Non-drinkers: OR = 0.44 (95% CI = 0.32–0.62, P = 0.002)
These results indicate that while genetic factors are influential, heavy environmental insults like tobacco and alcohol consumption may "override" or mask the inherent protection provided by certain genetic variants.
Functional Impact on BCL-2 Expression
Genotype-phenotype correlation studies provided a mechanistic explanation for the observed risk reduction. Subjects carrying the protective AA or CA genotypes showed a statistically significant decrease in BCL-2 mRNA expression in both healthy and tumorous esophageal tissues compared to those with the CC genotype. Lower expression of this anti-apoptotic protein likely facilitates the clearance of cells with oncogenic mutations, thereby reducing the likelihood of tumor formation.
Conclusion
This study identifies the BCL-2 rs2279115 polymorphism as a significant contributor to ESCC susceptibility in Chinese populations. The findings highlight the importance of regulatory genetic variants in cancer etiology and suggest that the protective "AA" genotype operates by modulating BCL-2 expression levels. While these results are compelling, further research is required to validate these findings in diverse ethnic groups and to explore the broader apoptotic pathway interactions through protein-level validation and comprehensive pathway analysis.
Summary updated